The pharmaceutical supply chain is a network of various stakeholders such as manufacturers, distributors, logistics providers, pharmacies, and regulatory authorities. It is essential to ensure transparency, security, and trust among them to prevent counterfeit drugs, data manipulation, and financial fraud. Drug supply chains using traditional trade finance processes are heavily dependent on paper-based documentation and centralized systems. These practices often cause delays, result in high transaction costs, and reduce traceability.
This article introduces a Trade Finance Framework Powered by Blockchain for enhancing security in drug supply chain transactions. The framework utilizes blockchain technology to offer decentralized, tamper-proof record keeping and real-time transaction verification. Smart contracts facilitate the automation of trade finance procedures such as letter of credit validation, payment release, and compliance verification, thus cutting down on processing time and human intervention. A distributed ledger keeps a record of each transaction, which is accessible to all and cannot be altered, all while hiding sensitive data through encryption mechanisms.
The proposed system bolsters mutual trust among the different parties involved, increases the ability to trace pharmaceutical products, decreases the risks of fraud, and makes regulatory compliance easier. By combining blockchain with trade finance, the framework enables secure, effective, and transparent drug supply chain management, thus leading to higher patient safety and better financial accountability.
Keywords: Blockchain, Trade Finance, Drug Supply Chain, Smart Contracts, Secure Transactions, Distributed Ledger Technology, Transparency, Pharmaceutical Logistics.
How to cite this article: Latha KP, Reddy MNM, Rajalingam B, Akurati M, Swapna G, Kumar BS. Blockchain-enabled trade finance framework for secure drug supply chain transactions. Int J Drug Deliv Technol. 2026;16(3s): 884-889; DOI: 10.25258/ijddt.16.3s.108
Source of support: Nil.
Conflict of interest: None